Obesity trials recruiting in Arizona

All Obesity trials nationally

Cities in Arizona

Recruiting trials in Arizona

• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
  NCT07351045 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Tucson
• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
  NCT07351058 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Tucson
• A Culturally-relevant Micronutrient-dense Plant-rich (mNDPR) Dietary Intervention for Native Americans
  NCT04755062 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Flagstaff
• A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
  NCT06143956 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Arizona: Chandler, Phoenix, Scottsdale, Tucson
• A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
  NCT07667803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Chandler, Sun City
• A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors
  NCT07656727 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Chandler, Peoria, Tucson
• A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
  NCT06672549 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Arizona: Tucson
• A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
  NCT07481630 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Phoenix
• A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
  NCT07564414 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Gilbert, Phoenix
• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
  NCT07567001 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Gilbert, Glendale, Phoenix
• A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
  NCT07654374 · Phase: Phase 3 · Ages: 18 Years to 79 Years · Sex: All (male and female) · Arizona: Chandler, Phoenix, Sun City West, Tucson
• A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
  NCT07282600 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Tucson
• A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
  NCT07321886 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Scottsdale
• A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
  NCT07392190 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Phoenix, Scottsdale, Tucson
• A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
  NCT06897475 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Arizona: Phoenix
• A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
  NCT07215559 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Arizona: Gilbert, Phoenix, Tucson
• A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
  NCT07743450 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Peoria, Phoenix, Tucson
• A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
  NCT07743463 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Phoenix, Tempe, Tucson
• A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
  NCT07153471 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Phoenix, Tempe
• A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
  NCT07202884 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Female · Arizona: Mesa
• A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)
  NCT07575932 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Chandler, Sun City West, Tucson
• A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity
  NCT07724340 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Chandler
• A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
  NCT06836609 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Arizona: Chandler, Tucson
• A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
  NCT07784725 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Mesa
• A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
  NCT06864026 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Avondale, Chandler, Flagstaff, Gilbert
• A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
  NCT07589608 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Arizona: Chandler, Scottsdale, Tucson
• A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
  NCT06857942 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Phoenix
• A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
  NCT07441252 · Phase: Phase 2 · Ages: 18 Years to 99 Years · Sex: All (male and female) · Arizona: Chandler, Phoenix, Tucson
• AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
  NCT07571109 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Gilbert
• Adverse Outcomes and Mortality in Liver Transplant
  NCT05477277 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Phoenix
• Early Tracking of Childhood Health Determinants (ETCHED) Study
  NCT03481829 · Phase: Not specified · Ages: 1 Day to 99 Years · Sex: All (male and female) · Arizona: Phoenix
• Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
  NCT07654361 · Phase: Phase 3 · Ages: 18 Years to 79 Years · Sex: All (male and female) · Arizona: Phoenix, Sun City West, Tucson
• Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
  NCT07353931 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Mesa, Phoenix, Tucson
• Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity
  NCT07497880 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Arizona: Chandler, Phoenix
• Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
  NCT07284979 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Glendale, Phoenix
• Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
  NCT07284901 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Phoenix, Sun City
• Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
  NCT07284875 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Sun City
• Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
  NCT07575399 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · Arizona: Chandler, Sun City
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
  NCT07037433 · Phase: Phase 3 · Ages: 45 Years to 99 Years · Sex: All (male and female) · Arizona: Phoenix
• Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
  NCT07684144 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · Arizona: Gilbert
• Fibrosis Lessens After Metabolic Surgery
  NCT06374875 · Phase: Phase 4 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Arizona: Phoenix
• Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity
  NCT04232566 · Phase: Not specified · Ages: 30 Years to 70 Years · Sex: All (male and female) · Arizona: Scottsdale
• Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
  NCT07037459 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · Arizona: Phoenix, Tucson, Yuma
• Primary Prevention of Obesity in American Indian Youth in Rural Tribal Schools
  NCT06864468 · Phase: Not applicable (e.g. observational or device study) · Ages: 8 Years to 10 Years · Sex: All (male and female) · Arizona: Flagstaff
• Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
  NCT07446998 · Phase: Phase 2 · Ages: 65 Years to 100 Years · Sex: All (male and female) · Arizona: Phoenix
• Redefining Evaluation of Adiposity and Leanness: Broadening Objective Diagnostics for Obesity
  NCT07776678 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Phoenix
• Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
  NCT07752979 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Arizona: Scottsdale
• Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants
  NCT07673900 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · Arizona: Tempe
• Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
  NCT06499857 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Arizona: Phoenix
• The Effects of Increasing Caloric Intake on Diet-Induced Thermogenesis and 24h Energy Expenditure
  NCT05545306 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 60 Years · Sex: All (male and female) · Arizona: Phoenix
• Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose
  NCT06223555 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 99 Years · Sex: All (male and female) · Arizona: Phoenix
• WatchWell: Simple and Practical Strategies to Reduce the Negative Health Impact of Sedentary Screen Time
  NCT06963736 · Phase: Not applicable (e.g. observational or device study) · Ages: 26 Years and older · Sex: All (male and female) · Arizona: Tempe